The tweet was deleted by the author.
But we saved everything 🙂.
Ligand Pharmaceuticals is making significant financial strides by supporting Athira Pharma through a $90 million private placement financing round. This move aims to bolster the development of lasofoxifene, a promising Phase 3 oncology asset, strengthening Ligand's pharmaceutical pipeline.
The investment highlights Ligand's strategic focus on enriching its oncology portfolio through cutting-edge advancements. Lasofoxifene is attracting attention as it nears pivotal study phases, potentially offering substantial returns and expanding treatment options within the cancer therapy sector.